TGTX Stock Overview
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
TG Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.57 |
52 Week High | US$35.67 |
52 Week Low | US$6.46 |
Beta | 2.32 |
1 Month Change | 16.54% |
3 Month Change | -11.63% |
1 Year Change | 4.85% |
3 Year Change | -67.70% |
5 Year Change | 87.14% |
Change since IPO | 1,270.29% |
Recent News & Updates
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01Recent updates
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe
Feb 08TG Therapeutics: Double Down On Partial Clinical Hold Non-Issue
Jan 28TG Therapeutics: Elucidating The Upcoming Binary Event
Dec 27Shareholder Returns
TGTX | US Biotechs | US Market | |
---|---|---|---|
7D | 1.3% | 0.9% | 0.4% |
1Y | 4.8% | 10.3% | 28.8% |
Return vs Industry: TGTX underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: TGTX underperformed the US Market which returned 29.5% over the past year.
Price Volatility
TGTX volatility | |
---|---|
TGTX Average Weekly Movement | 11.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TGTX's share price has been volatile over the past 3 months.
Volatility Over Time: TGTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 264 | Mike Weiss | https://www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
TGTX fundamental statistics | |
---|---|
Market cap | US$2.25b |
Earnings (TTM) | US$12.67m |
Revenue (TTM) | US$233.66m |
177.9x
P/E Ratio9.6x
P/S RatioIs TGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TGTX income statement (TTM) | |
---|---|
Revenue | US$233.66m |
Cost of Revenue | US$14.13m |
Gross Profit | US$219.53m |
Other Expenses | US$206.86m |
Earnings | US$12.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.088 |
Gross Margin | 93.95% |
Net Profit Margin | 5.42% |
Debt/Equity Ratio | 62.6% |
How did TGTX perform over the long term?
See historical performance and comparison